LEUKEMIA SCREENING MARKET ANALYSIS

Leukemia Screening MarketSize and Trends

Global leukemia screening market is estimated to be valued at US$ 7.28 Bn in 2023 and is expected to reach US$ 11.66 Bn by 2030, exhibiting a compound annual growth rate (CAGR) of 7% during the forecast period. Rising incidence of leukemia, increasing demand for early diagnosis, and technological advancements in the field of diagnostics are the major factors driving the growth of the global leukemia screening market.

Global leukemia screening market is segmented into test type, disease type, age group, end user, and region. By disease type, the market is segmented into acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL), and others. AML is the most common type of leukemia, accounting for approximately 35% of all cases. CML is the second most common type, accounting for approximately 20% of all cases. ALL is the third most common type, accounting for approximately 30% of all cases. CLL is the fourth most common type, accounting for approximately 15% of all cases.

Figure 2. Global Leukemia Screening Market Share (%), By Disease type, 2023

Global Leukemia Screening Market Trends

• Increasing adoption of genomic profiling: Genomic profiling is gaining traction in leukemia screening. It involves analyzing the genetic alterations and mutations in leukemia cells to determine the subtype and guide treatment decisions. Next-generation sequencing (NGS) technologies are being increasingly used to perform comprehensive genomic profiling, thereby enabling a deeper understanding of leukemia genetics and aiding in personalized treatment strategies. For instance, on January 10, 2023, QIAGEN Digital Insights, the bioinformatics division of QIAGEN, announced that Munich Leukemia Laboratory, one of the world’s largest leukemia laboratories, has selected QIAGEN Clinical Insights (QCI) Interpret to support the analysis, interpretation, and reporting of Illumina’s TruSight Oncology 500 Assay, a comprehensive genomic profiling test for solid tumors.
• Rise of liquid biopsy for minimal residual disease (MRD) monitoring: Liquid biopsy techniques, such as analyzing circulating tumor DNA (ctDNA) or other biomarkers in blood samples, are being utilized for minimal residual disease monitoring in leukemia patients. These non-invasive tests can provide real-time information on treatment response, disease recurrence, and the emergence of resistance mutations. Liquid biopsy-based MRD monitoring is becoming an integral part of leukemia management and is expected to witness further advancements.
• Integration of artificial intelligence and machine learning: Artificial intelligence (AI) and machine learning (ML) algorithms are being integrated into leukemia screening processes to enhance accuracy and efficiency. These technologies aid in analyzing complex datasets, identifying disease patterns, and predicting patient outcomes. AI-powered algorithms can assist pathologists in interpreting screening results and facilitate faster and more accurate diagnosis, thus ultimately improving patient care.
• Focus on precision medicine and targeted therapies: Precision medicine approaches, including targeted therapies and immunotherapies, are transforming the landscape of leukemia treatment. As screening techniques become more refined, they enable the identification of specific genetic alterations and biomarkers that can guide the selection of targeted therapies. The growing availability of targeted therapies tailored to specific leukemia subtypes is driving the demand for accurate and comprehensive screening.